Dashboard
Manage Tickers

VTVT vTv Therapeutics Inc.

Nasdaq vtvtherapeutics.com


$ 21.64 $ 0.68 (3.23 %)    

Friday, 31-Oct-2025 15:39:07 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 21.75
$ 20.26
$ 18.99 x 20
$ 24.77 x 50
$ 20.04 - $ 21.89
$ 12.62 - $ 26.99
3,094
na
69.48M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-03-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 10-30-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 02-24-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-02-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-04-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-amd-shares-are-trading-higher-by-over-34-here-are-20-stocks-moving-premarket
Why AMD Shares Are Trading Higher By Over ...
10/06/2025 13:01:08

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
10/06/2025 12:08:40

vtv-therapeutics-enters-80m-pipe-financing-with-institutional-investors-and-the-t1d-fund
vTv Therapeutics Enters $80M PIPE Financin...
09/02/2025 12:04:32

hc-wainwright--co-reiterates-buy-on-vtv-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on vTv ...
08/13/2025 11:40:50

HC Wainwright & Co. analyst Emily Bodnar reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $36 price ta...

vtv-therapeutics-q2-eps-092-misses-082-estimate
vTv Therapeutics Q2 EPS $(0.92) Misses $(0...
08/12/2025 20:17:40

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(...

united-states-patent-and-trademark-office-issued--notice-of-allowance-for-vtv-therapeutics-patent-application-directed-to-compositions-of-matter-of-crystalline-forms-of-salts-and-co-crystals-of-cadisegliatin
United States Patent And Trademark Office ...
08/11/2025 12:06:36

vtv-therapeutics-announces-first-participant-has-been-randomized-in-its-phase-3-catt1-trial-evaluating-cadisegliatin-as-an-adjunctive-oral-treatment-to-insulin-in-adults-with-type-1-diabetes
vTv Therapeutics Announces First Participa...
08/07/2025 12:07:30

vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small mole...

vtv-therapeutics-appoints-michael-tung-as-evp-and-cfo-effective-immediately
vTv Therapeutics Appoints Michael Tung As ...
05/19/2025 13:04:41

vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M...

vtv-therapeutics-q1-eps-077-beats-092-estimate
vTv Therapeutics Q1 EPS $(0.77) Beats $(0....
05/15/2025 20:13:10

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0....

vtv-therapeutics-resumes-screening-in-phase-3-catt1-study-evaluating-cadisegliatin-as-adjunctive-therapy-for-type-1-diabetes
vTv Therapeutics Resumes Screening In Phas...
05/15/2025 16:07:20

this-couchbase-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Couchbase Analyst Begins Coverage On ...
04/09/2025 12:18:52

hc-wainwright--co-initiates-coverage-on-vtv-therapeutics-with-buy-rating-announces-price-target-of-36
HC Wainwright & Co. Initiates Coverage On ...
04/09/2025 11:23:47

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and anno...

vtv-therapeutics-q4-2024-gaap-eps-055-beats-087-estimate
vTv Therapeutics Q4 2024 GAAP EPS $(0.55) ...
03/20/2025 21:37:40

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0....

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
03/19/2025 17:06:05

fda-lifts-clinical-hold-on-vtv-therapeutics-phase-3-diabetes-trial-stock-surges
FDA Lifts Clinical Hold On vTv Therapeutic...
03/17/2025 17:59:28

vTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
03/17/2025 17:05:53

vtv-therapeutics-says-fda-has-lifted-clinical-hold-on-cadisegliatin-program-for-diabetes-catt1-phase-3-trial-expected-to-resume-following-submission-of-protocol-amendment-shortening-overall-duration-of-trial-from-12-to-6-months
vTv Therapeutics Says FDA Has Lifted Clini...
03/17/2025 12:31:36

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/11/2025 21:06:07

alliance-global-partners-initiates-coverage-on-vtv-therapeutics-with-buy-rating-announces-price-target-of-35
Alliance Global Partners Initiates Coverag...
12/09/2024 16:58:39

Alliance Global Partners analyst James Molloy initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and ann...

vtv-therapeutics-q3-eps-088-up-from-319-yoy
vTv Therapeutics Q3 EPS $(0.88) Up From $(...
11/12/2024 22:14:40

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.88) per share. This is a 72.41 percent increase over losses of ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION